<DOC>
	<DOCNO>NCT00293150</DOCNO>
	<brief_summary>The principle aim determine efficacy eplerenone patient diastolic heart failure reverse cardiac remodel improve diastolic function .</brief_summary>
	<brief_title>Reversing Endothelial Diastolic Dysfunction Improving Collagen Turnover Diastolic Heart Failure</brief_title>
	<detailed_description>The study single center , double-blind , randomize , parallel group trial enrol minimum 80 patient design determine efficacy eplerenone subject diastolic heart failure . Prior administration study medication , medical history , physical exam , blood draw , electrocardiogram , 2D echocardiogram , cardiomyopathy questionnaire perform . Subjects randomize receive either eplerenone 25 mg daily placebo 2 week . At Week 2 visit patient titrate next dose ( 50 mg eplerenone daily placebo ) . Each study arm 40 subject participate 9 month . Follow-up assessment complete 1 week , 2 week , 1 month , 3 month , 6 month , 9 month . Starting Month 1 visit , subject uncontrolled blood pressure administer add-on therapy HCTZ ( start dose 12.5 mg daily , may titrate 25 mg daily ) and/or amlodipine ( start dose 5 mg daily , may titrate 10 mg daily ) . Any subject receive add-on therapy must blood pressure check within 2 week . Uncontrolled blood pressure may treat either increase add-on therapy dose increase add-on therapy regimen include add-on drug . Changes add-on therapy require blood pressure check within 2 week .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Patients must meet follow inclusion criterion eligible enrollment study : 1 . Male nonpregnant female ( female , either postmenopausal , childbearing potential , use adequate contraception e.g . hormonal barrier method , surgically sterile , lactate ) 2 . Age &gt; /= 18 year age 3 . Present prior history symptom heart failure ( dyspnea , fatigue ) consistent diagnosis diastolic heart failure , follow optimized medical therapy include blood pressure control ACE inhibitor and/or betablockers 2 week . 4 . Echocardiographic evidence preserve left ventricular systolic function ( LVEF &gt; /= 45 % ) evidence diastolic dysfunction ( transmitral inflow , pulmonary venous flow , color Mmode and/or tissue Doppler ) . 5 . Signed informed consent The presence follow exclude patient study enrollment : 1 . Unwilling participate 9month duration study 2 . Significant primary valvular , pulmonary congenital cardiac disease believe cause dyspnea 3 . Life expectancy plan cardiac transplantation &lt; 9 month 4 . History hypertrophic obstructive cardiomyopathy 5 . Unstable angina ischemia require revascularization 6 . Renal insufficiency ( Cr &gt; 2.0 mg/dL male &gt; 1.8 mg/dl female , modify CockcroftGault estimate creatinine clearance &lt; 30 mL/min ) enrollment 7 . Known hypersensitivity spironolactone eplerenone 8 . Decompensated heart failure clinical evidence instability time enrollment 9 History hyperkalemia ( &gt; 6.0 mg/dL ) spironolactone 10 . Use spironolactone amiloride within 30 day 11 . Poorly control seat blood pressure time drug initiation : Systolic blood pressure &gt; 160 mmHg ; and/or Diastolic blood pressure &gt; 100 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>diastolic heart failure</keyword>
	<keyword>heart failure</keyword>
</DOC>